Market Place
Sourcing Support
Galmed Publishes Aramchol Phase 3 Results In Hepatology
25 Sep 2024 //
PR NEWSWIRE
Galmed Files Annual Report on Form 20-F for the Fiscal Year Ended Dec 31, 2023
04 Apr 2024 //
PR NEWSWIRE
Galmed Announces Grant of Patent for Combination of Aramchol with Resmetirom
15 Mar 2024 //
PR NEWSWIRE
Galmed Announces a delay in the initiation of PSC Phase 2a Study
20 Nov 2023 //
PR NEWSWIRE
Galmed Announces Allowance of New Patent for Aramchol
26 Sep 2023 //
PR NEWSWIRE
Galmed Pharma Announces Receipt of Nasdaq Minimum Bid Price Notification
22 Sep 2023 //
PR NEWSWIRE
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
14 Jul 2023 //
PR NEWSWIRE
Galmed to employ OnKai`s disruptive AI in Planned Phase 2a Trial in PSC
10 Jul 2023 //
PR NEWSWIRE
Galmed Reports First Quarter 2023 Financial Results and Recent Developments
01 Jun 2023 //
PR NEWSWIRE
Galmed Announces Initiation of a Clinical DeVP to Evaluate Aramchol meglumine
09 May 2023 //
PR NEWSWIRE
Galmed Pharmaceuticals forms a Strategic Partnership with OnKai
04 May 2023 //
PR NEWSWIRE
Galmed Files Annual Report on Form 20-F for the Fiscal Year Ended December 31
29 Mar 2023 //
PR NEWSWIRE
Galmed Announces Issuance of Composition of Patent for Aramchol meglumine Salt
08 Feb 2023 //
PR NEWSWIRE
Galmed reports results from ARMOR study showing improvements
04 Jan 2023 //
PR NEWSWIRE
Galmed Announces Receipt of Extension to Meet Nasdaq`s Bid Price Requirement
14 Dec 2022 //
PRNEWSWIRE
Galmed Pharma Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis
07 Jul 2022 //
PRNEWSWIRE
Galmed Pharma Announces Receipt of Nasdaq Minimum Bid Price Notification
17 Jun 2022 //
PRNEWSWIRE
Galmed updates business & clinical strategy for Aramchol`s anti-fibrotic effects
17 May 2022 //
PRNEWSWIRE
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
17 May 2022 //
PRNEWSWIRE
Galmed Pharma Reports Fourth Quarter and Year End 2021 Financial Results
02 May 2022 //
PRNEWSWIRE
Galmed reports interim results from Open-Label part of ARMOR study with Aramchol
28 Apr 2022 //
PRNEWSWIRE
Galmed Pharma to Report Q4 and Year End 2021 Financial Results
26 Apr 2022 //
PRNEWSWIRE
Galmed Continues to Drive Innovation with 3 New US Patents Granted for Aramchol
11 Jan 2022 //
PRNEWSWIRE
Galmed Provides +ve Data from ARMOR Study; Reports Q3 2021 Financial Results
08 Nov 2021 //
PRNEWSWIRE
Aramchol™ reduces fibrosis progression in 24 weeks
01 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
Galmed Announces Positive Results from First 16 Patients in Open-Label Part
01 Nov 2021 //
YAHOO
Results of Galmed`s Phase 2b ARREST Trial Published in Nature Medicine
11 Oct 2021 //
PRNEWSWIRE
Galmed`s Amilo-5MER compound gets published in the Journal of Autoimmunity
19 Aug 2021 //
PRNEWSWIRE
MHRA Agrees with Galmed`s Plan to use Aramchol meglumine in Phase 3 ARMOR study
16 Aug 2021 //
PR NEWSWIRE
Galmed Provides Business Update & Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
PRNEWSWIRE
Galmed Pharma Provides Business Update and Reports Second Financial Results
05 Aug 2021 //
PRNEWSWIRE
FDA Agrees with Galmed`s Plan to use Aramchol Meglumine
02 Aug 2021 //
PRNEWSWIRE
Galmed Second Quarter 2021 Financial Results and Provide Business Update
29 Jul 2021 //
PRNEWSWIRE
Galmed Announces Approval of IND Application in China
03 May 2021 //
PRNEWSWIRE
Galmed Provides Business Update & Reports Q4 & Year End 2020 Financial Results
18 Mar 2021 //
PRNEWSWIRE
Galmed Announces Dosing of First Subject in First in Human Phase 1 Trial
16 Mar 2021 //
PRNEWSWIRE
Galmed Announces Pricing of $10 Million Public Offering of Ordinary Shares
16 Feb 2021 //
PRNEWSWIRE
Galmed Announces Upcoming Publication in JHEP Reports of New Data Supporting
26 Jan 2021 //
NASDAQ
Galmed Hosting KOL Symposium and Pipeline Update
18 Jan 2021 //
PRNEWSWIRE
Galmed to Report Third Quarter 2020 Financial Results and Provide Business
05 Nov 2020 //
PRNEWSWIRE
Gannex, Galmed enter into research agreement for NASH treatment
10 Sep 2020 //
BIOSPECTRUMASIA
Galmed collaborates with Gannex Pharma for development programs in NASH
08 Sep 2020 //
SEEKINGALPHA
